Fibrogen's anemia drug could be heart-healthy

There’s been lingering concern that Roxadusat, an experimental drug aimed at treating anemia among kidney disease patients, could have a major safety flaw: Last May, the San Francisco-based Fibrogen disclosed cardiac safety data on the potential blockbuster medicine that was less than reassuring. 

This past week, however, the drug maker released a Phase 3 analysis indicating the risk of an adverse cardiovascular event — that is, a heart attack, stroke, chest pain, or death — was statistically comparable to placebo.

Read more.